Werkgroep Cardiologische centra Nederland
Menu

TECOS (Completed)

A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (TECOS)
Medicine
Sitagliptin
Population
ASCVD
Phase
III
Starting year
2008
More information
Clinicaltrials.gov

Director of Study

prof. dr. J.H. Cornel (Cardioloog)
Alkmaar, Noordwest Ziekenhuisgroep

Publications: TECOS

  • Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS TrialCirculation - Abstract - Cornel, prof. dr. J.H. - TECOS - ASCVD
  • Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOSDiabetes Obes Metab - Abstract - Cornel, prof. dr. J.H. - TECOS - ASCVD
  • Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSDiabetes Care - Abstract - Cornel, prof. dr. J.H. - TECOS - ASCVD
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol. - Abstract - Cornel, prof. dr. J.H. - TECOS - ASCVD
  • Discussant review: impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine - TECOS - ASCVD

Publications by WCN study

Publications WCN studies by WCN member